In essence, these discoveries suggest that PDK1 contributes to the cancer growth and survival of BC cells, even without PI3 K oncogenic mutations, in either an AKT-dependent or AKT-independent fashion, which identifies PDK1 as a potential therapeutic target for BC. The gene discussed is AKT1; the disease is cancer.